MARKET

ALZN

ALZN

Alzamend Neuro Inc
NASDAQ
1.070
+0.010
+0.94%
Opening 09:35 03/31 EDT
OPEN
1.040
PREV CLOSE
1.060
HIGH
1.070
LOW
1.040
VOLUME
14.36K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
0.9800
MARKET CAP
4.07M
P/E (TTM)
-0.2332
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALZN last week (0323-0327)?
Weekly Report · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate
Benzinga · 5d ago
Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001
TipRanks · 5d ago
Alzamend Neuro reports Phase II AL001 trial meets bioequivalence; whole-brain lithium exposure rises ~7.8% vs. lithium carbonate
Reuters · 5d ago
ALZAMEND NEURO INC - ADDITIONAL PHASE II STUDIES IN MDD, PTSD, ALZHEIMER'S EXPECTED TO BEGIN IN LATTER HALF OF 2026
Reuters · 5d ago
Weekly Report: what happened at ALZN last week (0316-0320)?
Weekly Report · 03/23 09:58
Alzamend Neuro Receives Nasdaq Notice Over Equity Deficiency
TipRanks · 03/20 21:10
More
About ALZN
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Webull offers Alzamend Neuro Inc stock information, including NASDAQ: ALZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALZN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALZN stock methods without spending real money on the virtual paper trading platform.